The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index; 7 of the 8 sources its claims cite were checked for support.
BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions
Open accessAbstract
BCAS1 expression identifies newly formed and actively myelinating oligodendrocytes in development, adulthood, and disease.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
BCAS1 marks a transient population of newly formed, early myelinating oligodendrocytes in mouse and human brain that is distinct from oligodendrocyte progenitor cells and mature oligodendrocytes. BCAS1+ cells are abundant during developmental myelination, persist in adult gray matter, and are reformed in a proportion of chronic multiple sclerosis lesions, including inactive lesions.
Key findings
- BCAS1+ cells are oligodendroglial but segregate from known stages: in mouse, 16.5 ± 2.8% overlapped with NG2+ OPCs, 76.2 ± 3.5% with CC1, and 47.5 ± 3.2% with MAG; in human newborn tissue, only 3.5 ± 1.4% overlapped with NG2, 0.6 ± 0.3% with TPPP/p25, and 0% with CC1.
- BCAS1+ cells are transient in mouse corpus callosum: after 10 days of EdU labeling, 65 ± 2.7% of BCAS1+ cells incorporated EdU, but only 7.7 ± 1.3% remained after a 40-day chase; in somatosensory cortex, EdU+/BCAS1+ cells were 12.1 ± 1.5% at +0 days and 17.9 ± 1.1% at +40 days.
- Human white matter BCAS1+ density peaked in newborns at 154.7 ± 20.8 cells/mm², fell to 16.8 ± 4.5 cells/mm² at 2–8 years and 6.8 ± 2.3 cells/mm² at 18–26 years; frontal cortex BCAS1+ density remained 30–90 cells/mm² throughout adult life.
- In mouse somatosensory cortex, BCAS1+ myelinating oligodendrocyte density was 715.5 ± 66.8 cells/mm³ at P40, 379 ± 11.9 at 4 months, 347.7 ± 26.6 at 7 months, and 71.2 ± 11.7 at 21 months; SILAC showed higher 13C-lysine incorporation into myelin proteins in 1- and 4-month-old mice than in 18- and 26-month-old mice.
- In MS tissue, completely demyelinated chronic lesions rarely contained BCAS1+ oligodendrocytes, whereas partially remyelinated lesions contained clusters highest at the lesion border and within remyelinating areas; BCAS1+ cells were also found in completely inactive lesions.
Methods
- The study combined antibody validation, immunofluorescence/confocal imaging, transgenic lineage tracing (NG2-CreERT2, PLP-CreERT2, Sox10-CreERT2 × Esco2fl/fl), EdU pulse-chase, lysolecithin- and cuprizone-induced demyelination models, human autopsy and MS lesion tissue, human iPSC-derived oligodendrocytes, and SILAC-based mass spectrometry.
- Quantitative analyses were performed blinded, with no outlier removal; statistics used GraphPad Prism 6, including Kolmogorov-Smirnov normality testing, t tests or Mann-Whitney tests, and one-way ANOVA with post hoc tests or Kruskal-Wallis with Dunn’s multiple comparison tests.
Limitations
- Stated: human oligodendroglial morphology, metabolism, and function are less understood than in rodents; remyelination may operate on a different time scale and require additional cues in humans; lineage-tracing dynamics cannot be extrapolated to humans; the lifetime and cellular state of BCAS1+ cells in human brain and MS lesions are unknown, so whether they are newly formed or old cells locked in an intermediate state cannot be determined.
- Evident: human evidence is largely descriptive immunohistology, with newborn autopsy data from n = 3 and no direct human lineage tracing; the function of BCAS1 itself is unknown.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 of 8 cited sources checked · 4 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We examined our previously generated proteome database for oligodendrocyte specific proteins and noticed that BCAS1 was one of the most enriched proteins in oligodendrocytes (21).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1 expression identifies newly generated oligodendrocytes
What the sources say
- Partly supportedcites [21] Sharma K Schmitt S Bergner CG Tyanova S Kannaiyan N Manrique-Hoyos N Kongi K Cantuti L Hanisch U-K Philips M-A Rossner MJ Cell type- and brain region-resolved mouse brain proteome Nat Neurosci 2015 18 1819 1831 26523646 PMC7116867 sourceExperimental — accuracy not yet measured
The Results section describes a cell-type-resolved proteome and ranks proteins by enrichment in oligodendrocytes, supporting the identification of the previously generated database. But the passages naming enriched proteins do not mention BCAS1, and searches for BCAS1 and its expanded name found no passage establishing that it was among the most enriched. (LLM, conf=0.78)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A total of 17.1 ± 1.9% of these BCAS1+ cells displayed myelin segments with a patchy arrangement along the axons resembling the previously reported “intermittent myelin” of cortical pyramidal neurons (fig. S3B) (27).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ premyelinating and myelinating oligodendrocytes are present during development and in adult mice
What the sources say
- Supportedcites [27] Tomassy GS Berger DR Chen H-H Kasthuri N Hayworth KJ Vercelli A Seung HS Lichtman JW Arlotta P Distinct profiles of myelin distribution along single axons of pyramidal neurons in the neocortex Science 2014 344 319 324 24744380 PMC4122120 source
The paper reports intermittent myelination in layer II/III cortical pyramidal neurons, with myelinated axonal tracts intercalated with long unmyelinated segments (Fig. 2 and Fig. S3). The citation supports the comparison to that previously reported pattern; the 17.1 ± 1.9% figure describes the citing paper’s own BCAS1+ cells and is not attributed to this source. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, older patients are likely to remain receptive to regenerative therapies, which is in line with the conclusions drawn from experimental mouse models (41).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Discussion
What the sources say
- Partly supportedcites [41] Ruckh JM Zhao J-W Shadrach JL van Wijngaarden P Rao TN Wagers AJ Franklin RJM Rejuvenation of regeneration in the aging central nervous system Cell Stem Cell 2012 10 96 103 22226359 PMC3714794 sourceExperimental — accuracy not yet measured
The Discussion concludes that aged oligodendrocyte progenitor cells remain responsive to signals that promote repair and identifies them as potential targets for remyelination therapy, including in MS patients. The claim extends that conclusion from a specific CNS repair process to older patients’ receptiveness to regenerative therapies generally. (LLM, conf=0.84)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BCAS1+ oligodendrocytes are reformed after experimental demyelination and found in a proportion of chronic white matter lesions of patients with multiple sclerosis (MS) even in a subset of patients with advanced disease.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, immunostainings of the somatosensory cortex of adult wild-type mice showed that BCAS1+ myelinating oligodendrocytes were only positive for MAG and negative for PLP and that only few (17.7 ± 4.3%) expressed myelin basic protein (MBP), supporting our hypothesis that these cells constitute a distinct population of oligodendrocytes (fig. S3, D to G).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ premyelinating and myelinating oligodendrocytes are present during development and in adult mice
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The remaining cells were more differentiated, as shown by their reactivity with antibodies against mature oligodendrocytes such as adenomatous polyposis coli protein (76.2 ± 3.5% of overlap) (Fig. 1C; anti-adenomatous polyposis coli antibody, clone CC1) and myelin-associated glycoprotein (MAG; 47.5 ± 3.2% of overlap), a protein involved in oligodendrocyte and axon contact (Fig. 1C).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1 expression identifies newly generated oligodendrocytes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas all of the GFP+ premyelinating oligodendrocytes also showed immunoreactivity against BCAS1, most of the BCAS1+ premyelinating cells (70.5 ± 8.1% at P9 and 76.3 ± 1.7% at P14) did not express GFP, demonstrating that BCAS1 is expressed in a larger population of newly formed oligodendrocytes in the somatosensory cortex at both P9 and P14 (Fig. 2B).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ premyelinating and myelinating oligodendrocytes are present during development and in adult mice
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When the analysis was performed in the adult somatosensory cortex (at 4 months), we found that all BCAS1+ premyelinating oligodendrocytes were negative for GFP, suggesting that the previously identified PLP+ premyelinating oligodendrocytes constitute a subpopulation (29.5 ± 8.1% at P9,23.7 ± 1.7% at P14, and 0% at 4 months) of oligodendrocytes present only during development (Fig. 2B).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ premyelinating and myelinating oligodendrocytes are present during development and in adult mice
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We find that breast carcinoma amplified sequence 1 (BCAS1) expression identifies an oligodendroglial subpopulation in the mouse and human brain.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BCAS1+ oligodendrocytes are reformed after experimental demyelination and found in a proportion of chronic white matter lesions of patients with multiple sclerosis (MS) even in a subset of patients with advanced disease.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 8
- It may state two separate claims as one. 39
- The quote only partly states this claim. 1
Every source the paper cites for this claim was checked and supports it.
In the paper
“Birth dating of oligodendrocytes, by analysis of the integration of nuclear bomb test-derived14C into cells, provided evidence for the generation of only few new oligodendrocytes in the adult human corpus callosum (15), suggesting that adaptive myelination in the white matter of humans may be more limited as compared to mice.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Introduction
What the sources say
- Supportedcites [15] Yeung MSY Zdunek S Bergmann O Bernard S Salehpour M Alkass K Perl S Tisdale J Possnert G Brundin L Druid H Dynamics of oligodendrocyte generation and myelination in the human brain Cell 2014 159 766 774 25417154 source
The “Turnover of oligodendrocytes in humans” section reports carbon dating of oligodendrocyte DNA from the corpus callosum and finds that many cells persisted for decades. The section on oligodendrocyte number established in childhood estimates replacement of only 1 in 300 oligodendrocytes per year after age five. The supplied passages have no page numbers. (LLM, conf=0.94)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“BCAS1 was originally identified as mRNA amplified in human cancer cell lines (17), but recent transcriptome studies have shown that it is also highly expressed in the brain and, more specifically, in oligodendrocytes (18).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Introduction
What the sources say
- Could not verifycites [18] Zhang Y Chen K Sloan SA Bennett ML Scholze AR O’Keeffe S Phatnani HP Guarnieri P Caneda C Ruderisch N Deng S An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex J Neurosci 2014 34 11929 11947 25186741 PMC4152602 sourceExperimental — accuracy not yet measured
The Introduction and Abstract describe RNA-sequencing of mouse brain cell types, including oligodendrocytes, but the retrieved passages do not report BCAS1 expression. Searches for “BCAS1,” “Bcas1,” and its expanded name found no passage establishing that it is highly expressed in the brain or enriched in oligodendrocytes. (LLM, conf=0.72)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Birth dating of oligodendrocytes, by analysis of the integration of nuclear bomb test-derived14C into cells, provided evidence for the generation of only few new oligodendrocytes in the adult human corpus callosum (15), suggesting that adaptive myelination in the white matter of humans may be more limited as compared to mice.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Introduction
What the sources say
- Supportedcites [15] Yeung MSY Zdunek S Bergmann O Bernard S Salehpour M Alkass K Perl S Tisdale J Possnert G Brundin L Druid H Dynamics of oligodendrocyte generation and myelination in the human brain Cell 2014 159 766 774 25417154 source
The citation is attached to the finding that few new oligodendrocytes are generated in the adult human corpus callosum. The Highlights and “Different oligodendrocyte generation rates in mice and humans” report very limited turnover in human white matter and a much lower generation rate than in mice. The suggestion that adaptive myelination may be more limited is the citing authors’ inference, not a finding directly attributed to this source. (LLM, conf=0.92)
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“These data are in good agreement with the birth dating of oligodendrocytes by14C integration, which showed that the number of oligodendrocytes in the white matter is largely established during the first years, whereas gray matter oligodendrocytes continue to be generated in adulthood (15).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Discussion
What the sources say
- Supportedcites [15] Yeung MSY Zdunek S Bergmann O Bernard S Salehpour M Alkass K Perl S Tisdale J Possnert G Brundin L Druid H Dynamics of oligodendrocyte generation and myelination in the human brain Cell 2014 159 766 774 25417154 source
The section on corpus callosum oligodendrocyte numbers says their final complement is largely determined by around age five. The section on turnover dynamics says gray-matter oligodendrocyte numbers continue expanding until the fourth decade of life, based on ¹⁴C modeling. Page numbers are not available in the supplied copy. (LLM, conf=0.93)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We find that BCAS1+ oligodendrocytes are restricted to the fetal and early postnatal human white matter but remain in the cortical gray matter until old age.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, BCAS1+ cells were abundant in the fimbria at P7 and decreased until P21 (fig. S4, A to C).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ premyelinating and myelinating oligodendrocytes are present during development and in adult mice
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When we analyzed the corpus callosum and the fimbria hippocampi, a further prominent white matter tract, we found a significant increase in ENPP6+ cell bodies from P0 to P7 in the fimbria (P = 0.0291) and a significant decrease until P21 (P = 0.0405).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ premyelinating and myelinating oligodendrocytes are present during development and in adult mice
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hence, we found BCAS1+ oligodendrocytes to be distinct from NG2+oligodendrocyte progenitor cells, PLP+ premyelinating oligodendrocytes, and mature oligodendrocytes.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are largely restricted to the fetal and early postnatal human white matter but are numerous in the gray matter until old age
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In human tissue, ENPP6 colocalized with NG2 (74.4 ± 5.3%), and the overlap with BCAS1 was limited (12.2 ± 3.8%; fig. S11, B to F).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are largely restricted to the fetal and early postnatal human white matter but are numerous in the gray matter until old age
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BCAS1+ cells started to appear in the white matter at a gestational age of 17 to 27 weeks (37 ± 1.7 cells/mm2) and reached their highest values in newborns (154.7 ± 20.8 cells/mm2) before dropping to 16.8 ± 4.5 cells/mm2 in 2- to 8-year-old children. Their density reached 6.8 ± 2.3 cells/mm2 in 18- to 26-year-old individuals and remained low until old age (83 to 90 years old) (Fig. 5C).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are largely restricted to the fetal and early postnatal human white matter but are numerous in the gray matter until old age
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we quantified the amount of NG2+ oligodendrocyte progenitor cells in the white matter and found that the number of NG2+ cells also peaked in newborns (260 ± 57.3 cells/mm2), but in contrast to BCAS1+ cells, the density of NG2+ oligodendrocyte progenitor cells remained stable (166 ± 24 cells/mm2) throughout life into old age (Fig. 5C and fig. S12).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are largely restricted to the fetal and early postnatal human white matter but are numerous in the gray matter until old age
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the number of GFP+/BCAS1+ myelinating oligodendrocytes cells remained stable at 6 weeks after induction (Fig. 3G), we found a marked reduction in the number of GFP+/BCAS1+ premyelinating oligodendrocytes (reduction from 92.1 ± 3.1% in control to 29.5 ± 1.3% in the knockout; fig. S8C) and GFP+/ BCAS1+ myelinating oligodendrocytes (reduction from 97.6 ± 2.4% in control to 13.9 ± 7.3% in the”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ cells represent a transient population of oligodendrocytes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BCAS1 is a relatively short-lived protein with a lifetime of ~18 days [~155 days for MBP and ~188 days for PLP (calculations from our in vivo SILAC experiments); see Materials and Methods] that resides in the cytosolic spaces of oligodendrocytes and myelin and is down-regulated with differentiation.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As expected, we found an increase in the number of EdU+/CC1+ in BCAS1- cells at day 18 (but not significant at day 40), indicating their differentiation into a stable population of oligodendrocytes (Fig. 3D).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ cells represent a transient population of oligodendrocytes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BCAS1+ cells coexpressed OLIG2 and SOX10, suggesting oligodendroglial origin (Fig. 5, A and B).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are largely restricted to the fetal and early postnatal human white matter but are numerous in the gray matter until old age
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BCAS1 immunoreactivity is first seen in the soma but later appears in newly formed myelin sheaths”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BCAS1 was virtually excluded from the compacted myelin-like membrane sheets but remained at low levels in the cytosol-enriched, noncompacted areas (fig. S5C).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ cells represent a transient population of oligodendrocytes
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The density of the BCAS1+ oligodendrocytes was highest at the lesion border and within the remyelinating areas but low in the lesion core”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are reformed in a proportion of chronic white matter lesions in MS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, higher densities of BCAS1+ cells were identified already at P0 (in the fimbria), and BCAS1+ cells continued to be more abundant as compared to ENPP6+ cells in the corpus callosum and fimbria at P7 and in the corpus callosum at P21.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ premyelinating and myelinating oligodendrocytes are present during development and in adult mice
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that BCAS1+ oligodendrocytes were not only found in lesions with ongoing inflammatory and/or demyelinating activity but also in completely inactive lesions (Fig. 8, C and D)”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are reformed in a proportion of chronic white matter lesions in MS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the calculation of the13C/12C-lysine ratios revealed that the metabolism of neurofilaments had reached steady state in 4-month-old animals and remained at similar level throughout the life, we found that this was not the case for myelin proteins.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > Myelination continues into adulthood but declines in aged mice
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When we performed colabeling with markers for mature oligodendrocytes, tubulin polymerization promoting protein (TPPP/p25), and CC1, only very limited (0.6 ± 0.3% for TPPP/p25) or no overlap (0% for CC1), was seen (Fig. 5, A and B).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are largely restricted to the fetal and early postnatal human white matter but are numerous in the gray matter until old age
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, BCAS1+ oligodendrocytes are also distinct from TPPP/p25+ and CC1+ mature human oligodendrocytes but overlap fully with SOX10 and OLIG2”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When similar experiments were performed in the somatosensory cortex, we observed that only 12.1 ± 1.5% of the BCAS1+ cells incorporated EdU after 10 days of administration (+0 days; Fig. 3C). In contrast to the corpus callosum, the fraction of EdU+/BCAS1+ cells increased slightly to 17.9 ± 1.1% after 40 days of a chase (+40 days; Fig. 3C).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ cells represent a transient population of oligodendrocytes
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas a fraction of the BCAS1+ cells represent oligodendrocyte progenitor cells in mice, as determined by NG2 colabeling, the overlap is less than 5% in humans.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Discussion
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BCAS1+ myelinating oligodendrocytes were found at a density of 715.5 ± 66.8 cells/mm3 in young (P40) mice and remained as an abundant cell population in the adult mice (4 and 7 months of age), where they were found in the somatosensory cortex at a density of 379 ± 11.9 cells/mm3 (4 months) and 347.7 ± 26.6 cells/mm3 (7 months; Fig. 4A) and in the frontal cortex at a density of206.4 ± 57.8 cells/mm”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > Myelination continues into adulthood but declines in aged mice
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one. The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed that BCAS1+ cells decreased in the first week of feeding but already started to increase at week 3 and reached their highest densities at week 4, coinciding with remyelination (Fig. 6, C and D).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are reformed in a proportion of chronic white matter lesions in MS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As in mice, BCAS1+ cell bodies were not labeled with antibodies against PLP, whereas some cellswere stainedwith antibodies against MAG (9.8 ± 2.4% of overlap) and MBP (7.5 ± 1.4% of”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are largely restricted to the fetal and early postnatal human white matter but are numerous in the gray matter until old age
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We determined the fraction of cells with a myelinating morphology (segments aligned in parallel) and found the highest density in the 1- to 2-year-old individuals (36.7 ± 4.3% of all BCAS1+ cells), followed by the 6- to 16-year-old individuals (17.3 ± 4.9%), and 2 to 4% in the 38- to 40-year-old and 57- to 60-year-old individuals (Fig. 5G).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are largely restricted to the fetal and early postnatal human white matter but are numerous in the gray matter until old age
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that BCAS1+ oligodendrocytes are formed in the fetal and newborn brain, largely disappear from the adult white matter, and are reformed in MS lesions.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The number of BCAS1+ cells also declines in the white matter of adult mice, but in contrast to humans, they were present in relatively high density into adulthood before dropping to very low levels in old age.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Discussion
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These cells are newly formed, myelinating oligodendrocytes that segregate from oligodendrocyte progenitor cells and mature oligodendrocytes and mark regions of active myelin formation in development and in the adult.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“On average, in MS, only 20% of patients display efficient (above 60%) remyelination of lesions as shown by histochemistry in areas of pale myelin stain called “shadow plaques” (16).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Introduction
What the sources say
- Not checked — no full text of the sourcecites [16] Patrikios P Stadelmann C Kutzelnigg A Rauschka H Schmidbauer M Laursen H Sorensen PS Brück W Lucchinetti C Lassmann H Remyelination is extensive in a subset of multiple sclerosis patients Brain 2006 129 3165 3172 16921173 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, BCAS1+ cells represent a population of oligodendrocytes that are at an intermediate state of differentiation, segregating from both oligodendrocyte progenitor cells and mature oligodendrocytes.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ premyelinating and myelinating oligodendrocytes are present during development and in adult mice
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, the high ratios of13C-/12C-lysines in myelin proteins are consistent with prominent myelination at 1 month, still active myelination in 4-month-old mice but reduced myelin protein synthesis in aged mice.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > Myelination continues into adulthood but declines in aged mice
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When we quantified the density of GFP+ cells in the somatosensory cortex of tamoxifen-treated transgenic animals, we found that the number of GFP+ oligodendrocytes labeled 18 days after tamoxifen injection did not change over the 11 months of chase, suggesting that developmentally born myelinating oligodendrocytes survive into late adulthood and expand their myelin sheaths (fig. S10, E and F).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > Myelination continues into adulthood but declines in aged mice
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, BCAS1+ cells constitute a transient cell population in the corpus callosum but not in the cortex.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ cells represent a transient population of oligodendrocytes
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results suggested that generation of myelinating oligodendrocytes continues into adulthood but declines in aged mice.”
- Also stated in: § Myelination continues into adulthood but declines in aged mice · hedged
“Thus, our SILAC-based quantification provides further evidence that myelination continues into adulthood but declines in aged mice.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > Myelination continues into adulthood but declines in aged mice
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Myelination continues into adulthood but declines in aged mice · hedged
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results suggest that, in contrast to NG2+ oligodendrocyte progenitor cells, BCAS1+ cells are a transient cell population preferentially expressed during the active phase of myelination in the human white matter.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are largely restricted to the fetal and early postnatal human white matter but are numerous in the gray matter until old age
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“suggesting that recruitment of oligodendrocyte progenitor cells and stimulation of remyelination are at least in part independent of lesion activity.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ oligodendrocytes are reformed in a proportion of chronic white matter lesions in MS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We therefore conclude that in the cortex, BCAS1+ oligodendrocytes also represent a transient cell population being continuously generated from proliferating oligodendrocyte progenitor cells, albeit with a much longer lifetime as compared to the corpus callosum.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ cells represent a transient population of oligodendrocytes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At P7, BCAS1+ cells coexpressing MAG were found to be more abundant than ENPP6+/MAG+ cells, indicating that myelin protein expression starts earlier in BCAS1+ cells (fig. S4, D and E).”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Results > BCAS1+ premyelinating and myelinating oligodendrocytes are present during development and in adult mice
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The quantitative analyses were performed blinded.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Material and Methods > Study design
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“this difference is possibly attributed to differences in the expression pattern of CC1 in mice and human.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Discussion
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“No outlier removal was performed.”
§ BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions > Material and Methods > Study design
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
No molecular marker exists that allows discrimination of myelinated from remyelinated axons, and ongoing myelination is difficult to detect, so it has not been possible to determine whether new myelin sheaths are formed in chronically demyelinated MS lesions.
“Currently, no molecular marker exists that allows the discrimination of myelinated from remyelinated axons, and ongoing myelination is notoriously difficult to detect; consequently, it has thus far not been possible to determine whether new myelin sheaths are formed in chronically demyelinated MS lesions.”
The paper relies on this without support.
Failure of remyelination contributes to disease progression in MS.
“Because failure of remyelination contributes to disease progression in MS, remyelinating oligodendrocytes might represent an important drug target.”
The paper relies on this without support.
Whether and how brain activity modulates myelin changes is not well understood.
“However, human studies are often based on magnetic resonance imaging, which does not provide direct information on myelin; therefore, whether and how brain activity modulates myelin changes is not well understood.”
The paper relies on this without support.
Human studies of white matter changes upon learning and training are often based on magnetic resonance imaging, which does not provide direct information on myelin.
“However, human studies are often based on magnetic resonance imaging, which does not provide direct information on myelin; therefore, whether and how brain activity modulates myelin changes is not well understood.”
The paper relies on this without support.
Remyelinating oligodendrocytes might represent an important drug target in MS.
“Because failure of remyelination contributes to disease progression in MS, remyelinating oligodendrocytes might represent an important drug target.”
The paper relies on this without support.
The typical chronological sequence of myelination in the human white matter is established.
“the established typical chronological sequence of myelination in the white matter”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Myelin maintenance in white matter is actively regulated by the continuous proliferation and maturation of oligodendrocytes derived from progenitor cells throughout adulthood. 24 , 25”
From Apolipoprotein ε4 exacerbates white matter impairment in a mouse model of Aβ amyloidosis by decreasing actively myelinating oligodendrocytes (2025) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BCAS1+ oligodendrocytes are Olig2+ but do not express markers of oligodendrocyte precursor cells (e.g. NG2) and mature oligodendrocytes (e.g. CC1 or p25/TTTP), thus representing an intermediate stage of oligodendrocyte differentiation.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To quantify BCAS1+ cell morphology, a blinded observer categorized BCAS1+ cells as either ‘early‐myelinating’ (possessing multiple processes) or ‘pre‐myelinating’ (possessing few processes) as previously described (Fard et al. 2017; Bergner et al. 2024).”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Fard et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fard et al. also reported a significant decrease in the BCAS-1 cell number with cuprizone administration [20].”
From Multifaceted response of microglia in the cuprizone model of demyelination (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BCAS1‐positive oligodendrocytes serve as a marker for these actively myelinating oligodendrocytes and are distinct from both oligodendrocyte progenitor cells and mature oligodendrocytes. 25”
From Apolipoprotein ε4 exacerbates white matter impairment in a mouse model of Aβ amyloidosis by decreasing actively myelinating oligodendrocytes (2025) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Brain-enriched myelin-associated protein 1 (BCAS1) identifies oligodendrocyte lineage cells in the stage of active myelin formation in development and regeneration.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Other than in the white matter, BCAS1+ oligodendrocytes are maintained at high densities in the cortex throughout life.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“BCAS1+ oligodendrocytes are highly abundant in the white matter during developmental myelination but largely disappear in adulthood.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, in the cerebral cortex, the population of BCAS1+ oligodendrocytes remains substantial throughout life and only slowly decreases with age.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Notably, both pre‐myelinating and early‐myelinating oligodendrocytes express BCAS1 (Fard et al. 2017).”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Fard et al. 2017
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies showed that BCAS1 (breast carcinoma amplified sequence 1) is expressed by a subset of the oligodendrocyte lineage: newly differentiated, pre‐myelinating, and early‐myelinating oligodendrocytes that derive from NG2+ OPCs but do not yet express all mature oligodendrocyte markers (Chapman et al. 2024; Fard et al. 2017).”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Fard et al. 2017
Citations
Cites
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2467 · Cited by 6,907 · cited 1×
“We crossbred transgenic mice expressing a tamoxifen-inducible Cre DNA recombinase inserted into the NG2 locus [NG2-CreERT2 (22)] with a widely used reportermouse strain containing amembrane-targeted enhanced green fluorescent protein (EGFP) gene inserted into the Gt(ROSA)26Sor locus (23).”
MethodZhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875 · cited 1×
“BCAS1 was originally identified as mRNA amplified in human cancer cell lines (17), but recent transcriptome studies have shown that it is also highly expressed in the brain and, more specifically, in oligodendrocytes (18).”
BackgroundCell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq
Zeisel, A., Muñoz-Manchado, A. B., Codeluppi, S., Lönnerberg, P., La Manno, G., Juréus, A., Marques, S., Munguba, H., He, L., Betsholtz, C., et al. (2015) · Science · doi:10.1126/science.aaa1934 · Cited by 3,124 · cited 1×
“Recent single RNA sequencing transcriptome analyses confirm oligodendrocyte heterogeneity (35, 36).”
BackgroundBiology of Oligodendrocyte and Myelin in the Mammalian Central Nervous System
Baumann, N., & Pham-Dinh, D. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.871 · Cited by 1,828
Plasticity in gray and white: neuroimaging changes in brain structure during learning
Zatorre, R. J., Fields, R. D., & Johansen-Berg, H. (2012) · Nature Neuroscience · doi:10.1038/nn.3045 · Cited by 1,685
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544
Extensive piano practicing has regionally specific effects on white matter development
Bengtsson, S. L., Nagy, Z., Skare, S., Forsman, L., Forssberg, H., & Ullén, F. (2005) · Nature Neuroscience · doi:10.1038/nn1516 · Cited by 1,193
Motor skill learning requires active central myelination
McKenzie, I. A., Ohayon, D., Li, H., Paes de Faria, J., Emery, B., Tohyama, K., & Richardson, W. D. (2014) · Science · doi:10.1126/science.1254960 · Cited by 1,177
Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system
Marques, S., Zeisel, A., Codeluppi, S., van Bruggen, D., Mendanha Falcão, A., Xiao, L., Li, H., Häring, M., Hochgerner, H., Romanov, R. A., et al. (2016) · Science · doi:10.1126/science.aaf6463 · Cited by 1,132 · cited 1×
“Recent single RNA sequencing transcriptome analyses confirm oligodendrocyte heterogeneity (35, 36).”
BackgroundPremyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 3×
“PLP is one of the major structural proteins in myelin and therefore not only highly expressed in mature myelin-forming oligodendrocytes but also present in premyelinating cells during development (24).”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes‐Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 799
“Chronic active lesions do not regularly contain areas of remyelination, but nevertheless may show an activation and expansion of premyelinating and early myelinating oligodendrocytes (175).”
BackgroundSelf-citationNeuronal vulnerability and multilineage diversity in multiple sclerosis
Schirmer, L., Velmeshev, D., Holmqvist, S., Kaufmann, M., Werneburg, S., Jung, D., Vistnes, S., Stockley, J. H., Young, A., Steindel, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1404-z · Cited by 638
Remyelination in multiple sclerosis: From basic science to clinical translation
Lubetzki, C., Zalc, B., Williams, A., Stadelmann, C., & Stankoff, B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30140-x · Cited by 350
Self-citationCD8+ T cells induce interferon-responsive oligodendrocytes and microglia in white matter aging
Kaya, T., Mattugini, N., Liu, L., Ji, H., Cantuti-Castelvetri, L., Wu, J., Schifferer, M., Groh, J., Martini, R., Besson-Girard, S., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01183-6 · Cited by 224
Self-citationMyelin Dynamics Throughout Life: An Ever-Changing Landscape?
Williamson, J., & Lyons, D. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00424 · Cited by 194
“Immunohistochemical analysis of human brain tissue using a novel marker for newly differentiated oligodendrocytes (BCAS1) shows new oligodendrocytes in the frontal cortex even beyond middle-age, but very few new oligodendrocytes in white matter after the third decade of life (Fard et al., 2017).”
BackgroundOligodendrocytes Provide Antioxidant Defense Function for Neurons by Secreting Ferritin Heavy Chain
Mukherjee, C., Kling, T., Russo, B., Miebach, K., Kess, E., Schifferer, M., Pedro, L. D., Weikert, U., Fard, M. K., Kannaiyan, N. R., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.05.019 · Cited by 195
“We used mass spectrometry data obtained from isolated myelin derived from 18 month-old C57BL/6 wildtype mice that had been fed with an isotopically labeled 13C-lysine stable isotope labeling with amino acids (SILAC) diet for 30 or 60 days (Fard et al., 2017).”
Self-citationCunha, M. I., Su, M., Cantuti-Castelvetri, L., Müller, S. A., Schifferer, M., Djannatian, M., Alexopoulos, I., van der Meer, F., Winkler, A., van Ham, T. J., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191390 · Cited by 160
“2 to assess the number of OPCs, against BCAS1 to visualize premyelinating and myelinating oligodendrocytes (Fard et al., 2017) and against APC (CC1) to mark mature oligodendrocytes in 7 and 21 dpi lesions.”
Self-citationMolecular cascades and cell type–specific signatures in ASD revealed by single-cell genomics
Wamsley, B., Bicks, L. K., Cheng, Y., Kawaguchi, R., Quintero, D., Grundman, J., Liu, J., Xiao, S., Hawken, N., Margolis, M., et al. (2024) · Science · doi:10.1126/science.adh2602 · Cited by 155
“…most-mature myelination profile, and OPCS1 being immature cells, whereas OPCS3 were delineated by BCAS1 (brain enriched myelin associated protein 1) and GPR17 (G protein – coupled receptor 17), which indicates that they are a specific type of OPC that supports synaptic function ( 24 , 25 ) (fig.”
BackgroundCaglayan, E., Liu, Y., & Konopka, G. (2022) · Neuron · doi:10.1016/j.neuron.2022.09.010 · Cited by 123
White matter aging and its impact on brain function
Groh, J., & Simons, M. (2025) · Neuron · doi:10.1016/j.neuron.2024.10.019 · Cited by 124
Self-citationInflammation in multiple sclerosis: consequences for remyelination and disease progression
Klotz, L., Antel, J. P., & Kuhlmann, T. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00801-6 · Cited by 125
Self-citationTepavčević, V., & Lubetzki, C. (2022) · Brain · doi:10.1093/brain/awac307 · Cited by 115
Premyelinating Oligodendrocytes: Mechanisms Underlying Cell Survival and Integration
Hughes, E. G., & Stockton, M. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.714169 · Cited by 98
Chavali, M., Ulloa-Navas, M. J., Pérez-Borredá, P., García‐Verdugo, J. M., McQuillen, P. S., Huang, E. J., & Rowitch, D. H. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.033 · Cited by 101
Oligodendrocytes: Myelination, Plasticity, and Axonal SupportPreprint
Simons, M., Gibson, E. M., & Nave, K. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041359 · Cited by 110
Self-citationEpigenomic priming of immune genes implicates oligodendroglia in multiple sclerosis susceptibility
Meijer, M., Agirre, E., Kabbe, M., van Tuijn, C. A., Heskol, A., Zheng, C., Mendanha Falcão, A., Bartosovic, M., Kirby, L., Calini, D., et al. (2022) · Neuron · doi:10.1016/j.neuron.2021.12.034 · Cited by 98
Timmler, S., & Simons, M. (2019) · Glia · doi:10.1002/glia.23614 · Cited by 82
“These data concur with the observation that BCAS1 premyelinating cells are generated until at least 1 year of age in mice (Fard et al., 2017).”
BackgroundResultInfluentialSelf-citationOligodendrocytes in Alzheimer’s disease pathophysiology
Kedia, S., & Simons, M. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01873-x · Cited by 86
“During this transition, they have to pass a particularly vulnerable premyelinating oligodendrocyte cell state, which is characterized by high biosynthetic activity, increasing susceptibility to endoplasmic reticulum stress and cell death 19 .”
Self-citationMyelin plasticity in adulthood and aging
Chapman, T. W., & Hill, R. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134645 · Cited by 101
“Consistent with this, recent work in human tissue has demonstrated continued generation of new oligodendrocyte in the cerebral cortex [33].”
ResultPepper, R., Pitman, K. A., Cullen, C. L., & Young, K. M. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00399 · Cited by 86
Development of myelinating glia: An overview
Cristobal, C. D., & Lee, H. K. (2022) · Glia · doi:10.1002/glia.24238 · Cited by 85
“…recently, protein and mRNA levels of the myelin associated protein BCAS1 were found to increase in pre- myelinating OLs in human and mouse tissues (Fard et al., 2017), and transcripts of BMP4 and ENPP6 in mice, potentially serving as new distinct markers for this intermediate stage (Hughes…”
BackgroundPathological potential of oligodendrocyte precursor cells: terra incognita
Yi, C., Verkhratsky, A., & Niu, J. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.04.003 · Cited by 83
Two adhesive systems cooperatively regulate axon ensheathment and myelin growth in the CNS
Djannatian, M., Timmler, S., Arends, M., Luckner, M., Weil, M., Alexopoulos, I., Snaidero, N., Schmid, B., Misgeld, T., Möbius, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12789-z · Cited by 83
Self-citationXu, J., Zhang, L., Li, M., He, X., Luo, J., Wu, R., Hong, Z., Zheng, H., & Hu, X. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02741-w · Cited by 84
“That is to say, PE promotes remyelination after stroke via enhanced oligodendrocyte differentiation, as BCAS1 expression could identify newly generated oligodendrocytes [36].”
BackgroundMitogenic and progenitor gene programmes in single pilocytic astrocytoma cells
Reitman, Z. J., Paolella, B. R., Bergthold, G., Pelton, K., Becker, S., Jones, R. E., Sinai, C. E., Malkin, H., Huang, Y., Grimmett, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11493-2 · Cited by 78
Oligodendrogenesis and myelination regulate cortical development, plasticity and circuit function
Fletcher, J. L., Makowiecki, K., Cullen, C. L., & Young, K. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.03.017 · Cited by 82
Maas, D. A., Eijsink, V. D., Spoelder, M., van Hulten, J. A., Weerd, P. D., Homberg, J. R., Vallès, A., Nait‐Oumesmar, B., & Martens, G. J. M. (2020) · Nature Communications · doi:10.1038/s41467-020-16218-4 · Cited by 75
Macron, C., Lane, L., Galindo, A. N., & Dayon, L. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00300 · Cited by 77
Diversity and Function of Glial Cell Types in Multiple Sclerosis
Schirmer, L., Schafer, D. P., Bartels, T., Rowitch, D. H., & Calabresi, P. A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.01.005 · Cited by 78
“However, recent work using sc/snRNA-seq and proteomic studies has highlighted a high level of transcriptomic heterogeneity comprising several immature OPC and myelinating OL subtypes (Box 2, Figure 3), especially under chronic inflammatory–demyelinating conditions such as mouse EAE and human MS [5,10,27].”
ResultKohnke, S., Buller, S. A., Nuzzaci, D., Ridley, K., Lam, B., Pivoňková, H., Bentsen, M. A., Alonge, K. M., Zhao, C., Tadross, J. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109362 · Cited by 74
“In the adult human brain, BCAS1 is marker of newly formed oligodendrocytes (NFOLs) (Fard et al., 2017).”
BackgroundMicroglia Diversity in Health and Multiple Sclerosis
Zia, S., Rawji, K. S., Michaels, N. J., Burr, M. K., Kerr, B. J., Healy, L. M., & Plemel, J. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588021 · Cited by 70
Chapman, T. W., Olveda, G. E., Bame, X., Pereira, E., & Hill, R. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01271-1 · Cited by 66
Dimovasili, C., Fair, A. E., Garza, I., Batterman, K. V., Mortazavi, F., Moore, T. L., & Rosene, D. L. (2022) · GeroScience · doi:10.1007/s11357-022-00621-4 · Cited by 74
“Thus, in the adult brain, BCAS1 + cells constitute a population of potentially re-myelinating oligodendrocytes [44].”
BackgroundResultInfluentialHigh-Frequency Microdomain Ca2+ Transients and Waves during Early Myelin Internode Remodeling
Battefeld, A., Popovic, M. A., de Vries, S. I., & Kole, M. H. P. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.039 · Cited by 64
“Because there is a strong age-dependent reduction in newly formed oligodendrocytes after myelin development (Fard et al., 2017), our low rate of Ca events in myelin sheaths in adulthood may reflect a reduced probability to target newly formed OLs.”
BackgroundAn atlas of late prenatal human neurodevelopment resolved by single-nucleus transcriptomics
Ramos, S. I., Mussa, Z. M., Falk, E. N., Pai, B., Giotti, B., Allette, K., Cai, P., Dekio, F., Sebra, R., Beaumont, K. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34975-2 · Cited by 59
Remyelination by surviving oligodendrocytes is inefficient in the inflamed mammalian cortex
Mezydlo, A., Treiber, N., Ullrich Gavilanes, E. M., Eichenseer, K., Ancău, M., Wens, A., Ares Carral, C., Schifferer, M., Snaidero, N., Misgeld, T., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.03.031 · Cited by 63
Bormann, D., Knoflach, M., Poreba, E., Riedl, C. J., Testa, G., Orset, C., Levilly, A., Cottereau, A., Jauk, P., Hametner, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50465-z · Cited by 65
Ghorbani, S., Jelinek, E., Jain, R. W., Buehner, B. J., Li, C., Lozinski, B. M., Sarkar, S., Kaushik, D. K., Dong, Y., Wight, T. N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30032-0 · Cited by 57
Zhao, Y., Zhu, W., Wan, T., Zhang, X., Li, Y., Huang, Z., Xu, P., Huang, K., Ye, R., Xie, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34293-7 · Cited by 62
Couturier, C., Nadaf, J., Li, Z., Baig, S., Riva, G., Le, P. U., Kloosterman, D. J., Monlong, J., Nkili-Meyong, A. A., Allache, R., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac085 · Cited by 55
Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics
Rexach, J. E., Cheng, Y., Chen, L., Polioudakis, D., Lin, L., Mitri, V., Elkins, A., Han, X., Yamakawa, M., Yin, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.019 · Cited by 59
Remyelination protects neurons from DLK-mediated neurodegeneration
Duncan, G. J., Ingram, S. D., Emberley, K., Hill, J. Q., Cordano, C., Abdelhak, A., McCane, M., Jenks, J. E., Jabassini, N., Ananth, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53429-5 · Cited by 46
“KOOLsareproducedinsimilarproportionsinbothMyrf Δ iPlp1 and Myrf Δ iSox10 when examined as the percentage of nuclei by snRNA-seq (Supplementary Fig.”
Meng, F., Siu, G. G., Mok, B. W.-Y., Sun, J., Fung, K. S. C., Lam, J. Y.-W., Wong, N. K., Gedefaw, L., Luo, S., Lee, T. M. H., et al. (2021) · Cells · doi:10.3390/cells10071762 · Cited by 42
“2, was reported with a role in myelinating oligodendrocytes related to multiple sclerosis lesions [44].”
BackgroundKim, S., Lee, J., Koh, I. G., Ji, J., Kim, H. J., Kim, E., Park, J., Park, J.-E., & An, J. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01328-6 · Cited by 48
Go, V., Sarıkaya, D., Zhou, Y., Bowley, B. G. E., Pessina, M. A., Rosene, D. L., Zhang, Z. G., Chopp, M., Finklestein, S. P., Medalla, M., et al. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113540 · Cited by 43
Fagiani, F., Pedrini, E., Taverna, S., Brambilla, E., Murtaj, V., Podini, P., Ruffini, F., Butti, E., Braccia, C., Andolfo, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101680 · Cited by 45
Self-citationPatient iPSC models reveal glia-intrinsic phenotypes in multiple sclerosis
Clayton, B. L. L., Barbar, L., Sapar, M., Kalpana, K., Rao, C., Migliori, B., Rusielewicz, T., Paull, D., Brenner, K., Moroziewicz, D., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.08.002 · Cited by 38
Myelin Plasticity and Repair: Neuro-Glial Choir Sets the Tuning
Ronzano, R., Thétiot, M., Lubetzki, C., & Desmazières, A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00042 · Cited by 42
Fiore, F., Alhalaseh, K., Dereddi, R. R., Torres, F. B., Çoban, İ., Harb, A., & Agarwal, A. (2023) · Nature Communications · doi:10.1038/s41467-023-43920-w · Cited by 40
Patient-derived antibodies reveal the subcellular distribution and heterogeneous interactome of LGI1
Ramírez‐Franco, J., Debreux, K., Extrémet, J., Maulet, Y., Belghazi, M., Villard, C., Sangiardi, M., Youssouf, F., Far, L. E., Lévêque, C., et al. (2022) · Brain · doi:10.1093/brain/awac218 · Cited by 35
High-resolution transcriptomics informs glial pathology in human temporal lobe epilepsy
Pai, B., Tomé-García, J., Cheng, W. S., Nudelman, G., Beaumont, K. G., Ghatan, S., Panov, F. E., Caballero, E., Sarpong, K., Marcuse, L. V., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01453-1 · Cited by 38
Veturi, Y., Lucas, A., Bradford, Y., Hui, D., DUDEK, S. M., Theusch, E., Verma, A., Miller, J. E., Kullo, I. J., Hakonarson, H. H., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00879-y · Cited by 32
Regulators of Oligodendrocyte DifferentiationPreprint
Emery, B., & Wood, T. L. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041358 · Cited by 36
Lin, J.-P., Brake, A., Donadieu, M., Lee, A., Smith, G., Hu, K., Nair, G., Kawaguchi, R., Sati, P., Geschwind, D. H., et al. (2025) · Science · doi:10.1126/science.adp6325 · Cited by 35
Transcriptional profiles of mouse oligodendrocyte precursor cells across the lifespan
Heo, D., Kim, A. A., Neumann, B., Doze, V. N., Xu, Y. K. T., Mironova, Y. A., Slosberg, J., Goff, L. A., Franklin, R. J. M., & Bergles, D. E. (2025) · Nature Aging · doi:10.1038/s43587-025-00840-2 · Cited by 42
“In addition, OPCs in later stages of differentiation were defined by module 2, with many zinc-finger proteins (for example, Zfp36 and Zfp365 ) and canonical differentiation-associated genes (such as Myrf and Bcas1 ) 26,47 demonstrating high weights in this module (Fig.”
Papiol, S., Keeser, D., Hasan, A., Schneider-Axmann, T., Raabe, F. J., Degenhardt, F., Rossner, M. J., Bickeböller, H., Cantuti‐Castelvetri, L., Simons, M., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0618-z · Cited by 32
Self-citationGruchot, J., Lewen, I., Dietrich, M., Reiche, L., Sindi, M., Hecker, C., Herrero, F., Charvet, B., Weber‐Stadlbauer, U., Hartung, H., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308187120 · Cited by 34
“Furthermore, densities of early (re)myelinating oligodendrocytes marked by their expression of the breast carcinoma amplified sequence 1 (Bcas1) protein (27), were also significantly reduced in transgenic tissues at all stages analyzed.”
BackgroundFractalkine signaling regulates oligodendroglial cell genesis from SVZ precursor cells
Watson, A. E. S., de Almeida, M. M. A., Dittmann, N. L., Li, Y., Torabi, P., Footz, T. K., Vetere, G., Galleguillos, D., Sipione, S., Cardona, A. E., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.06.010 · Cited by 34
“Scale bars, 20 mm (B and G), A 3 mo. Endpoint Tamoxifen 5 days 7-day VC or FKN infusion NestinCreERT2; RosaYFPSTOP/+ SVZ WM 0 20 40 60 80 % YF P+ c el ls in a re a /to ta l Y FP + ce lls B C % YF P+ PD G FR α+ / YF P+ ce lls S VZ E SV Z W M SV Z W M D % YF P+ PD G FR α+ / YF P+ ce lls W M F 0 20 40 60 80 0 10 20 30 40…”
BackgroundInfluentialOligodendrocyte Maturation Alters the Cell Death Mechanisms That Cause Demyelination
Chapman, T. W., Kamen, Y., Piedra, E. T., & Hill, R. A. (2024) · The Journal of Neuroscience · doi:10.1523/jneurosci.1794-23.2024 · Cited by 33
Macroglial diversity: white and grey areas and relevance to remyelination
Werkman, I. L., Lentferink, D. H., & Baron, W. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03586-9 · Cited by 33
A Matter of State: Diversity in Oligodendrocyte Lineage Cells
Kamen, Y., Pivoňková, H., Evans, K. A., & Káradóttir, R. T. (2021) · The Neuroscientist · doi:10.1177/1073858420987208 · Cited by 35
Many roles for oligodendrocyte precursor cells in physiology and pathology
Nishiyama, A., Serwanski, D. R., & Pfeiffer, F. (2021) · Neuropathology · doi:10.1111/neup.12732 · Cited by 31
“4), and additional markers have been identified from the single-cell RNA-sequencing data.(59,60,63) It is worth mentioning here some caveats to using “cell typespecific markers.”
BackgroundPoggi, G., Albiez, J., & Pryce, C. R. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100451 · Cited by 31
Age and Alzheimer’s Disease-Related Oligodendrocyte Changes in Hippocampal Subregions
DeFlitch, L., González‐Fernández, E., Crawley, I., & Kang, S. H. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.847097 · Cited by 34
Guo, F., & Wang, Y. (2022) · Glia · doi:10.1002/glia.24249 · Cited by 34
Auderset, L., Pitman, K. A., Cullen, C. L., Pepper, R. E., Taylor, B. V., Foa, L., & Young, K. M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564351 · Cited by 30
Palhol, J. S. C., Balia, M., Terán, F. S.-R., Labarchède, M., Gontier, É., & Battefeld, A. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00425-4 · Cited by 30
Feng, R., Spieth, L., Liu, L., Berghoff, S. A., Franz, J., Liu, Q., Wang, Z., Tiwari, V., Vitale, S., Frerich, S., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.003 · Cited by 40
Self-citationHudson, K. M., Shiver, E., Yu, J., Mehta, S., Jima, D. D., Kane, M. A., Patisaul, H. B., & Cowley, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-95630-2 · Cited by 28
Identity and nature of neural stem cells in the adult human subventricular zone
Baig, S., Nadaf, J., Allache, R., Le, P. U., Luo, M., Djedid, A., Nkili-Meyong, A. A., Safisamghabadi, M., Prat, A., Antel, J. P., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109342 · Cited by 31
“Premyelinating oligodendrocyte genes BCAS1, SGK1, TCF7L2, and SCRG1 were also expressed in C9 (39, 40), as were genes involved in neuro-immune processes such as CD74, HLA-DRB1, and CXCR4 (41).”
BackgroundMOG-expressing teratoma followed by MOG-IgG-positive optic neuritis
Wildemann, B., Jarius, S., Franz, J., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02236-5 · Cited by 28
Self-citationDermitzakis, I., Μanthou, M. E., Meditskou, S., Miliaras, D., Kesidou, E., Boziki, M. K., Petratos, S., Grigoriadis, N., & Theotokis, P. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44070222 · Cited by 26
Decreased Oligodendrocyte Number in Hippocampal Subfield CA4 in Schizophrenia: A Replication Study
Schmitt, A., Tatsch, L., Vollhardt, A., Schneider-Axmann, T., Raabe, F. J., Roell, L., Heinsen, H., Hof, P. R., Falkai, P., & Schmitz, C. (2022) · Cells · doi:10.3390/cells11203242 · Cited by 27
“A decreased oligodendrocyte number indicates a deficit in the differentiation of oligodendrocyte precursor cells, which warrants more detailed evaluation in immunohistochemical postmortem studies of the CA4 with markers of oligodendrocyte precursors at the early myelination stage [54].”
BackgroundHallmarks of the cancer cell of origin: Comparisons with “energetic” cancer stem cells (e-CSCs)
Sotgia, F., Fiorillo, M., & Lisanti, M. P. (2019) · Aging · doi:10.18632/aging.101822 · Cited by 26
“BCAS1 over-expression [17] is functionally associated with “stemness” [18], a more aggressive cancer cell phenotype [19] and Tamoxifenresistance [20, 21].”
BackgroundFang, M., Chen, L., Tang, T., Qiu, M. S., & Xu, X. (2023) · Glia · doi:10.1002/glia.24426 · Cited by 28
Kasuga, Y., Fudge, A. D., Zhang, Y., & Li, H. (2019) · Glia · doi:10.1002/glia.23684 · Cited by 23
“This database categorizes gene expression into 13 different OL subtype/developmental stage clusters (Figure S5a) and reveals that Pcdh17it expression is elevated in two clusters of newly formed imOLs while Enpp6 and Bcas1 expression is scattered in numerous clusters of OL subtypes/stages (Figure S5b–d).”
BackgroundInfluentialCai, Y., Pinheiro‐de‐Sousa, I., Slobodyanyuk, M., Chen, F., Huynh, T., Kanyo, J. E., Tang, P., Fuentes, L. A., Braker, A., Welch, R., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01973-8 · Cited by 34
“Indeed, many spheroids in AD-like mice were labeled with BCAS1, the transient marker for newly formed oligodendrocytes and myelin 96 (Fig.”
Torii, T., Miyamoto, Y., Nakata, R., Higashi, Y., Shinmyo, Y., Kawasaki, H., Miyasaka, T., & Misonou, H. (2022) · Glia · doi:10.1002/glia.24322 · Cited by 25
“Subsequently, brain enriched myelin associated proteins 1 (BCAS1) (Fard et al., 2017), G protein-couple receptor 17 (GPR17) (Chen et al., 2009), and myelin regulator factor (MyRF) (Emery et al., 2009) among others are expressed to regulate oligodendrocyte 1002 © 2022 Wiley Periodicals LLC. Glia.”
BackgroundSengottuvel, V., Hota, M., Oh, J., Galam, D. L. A., Wong, B. H., Wenk, M. R., Ghosh, S., Torta, F. T., & Silver, D. L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164118 · Cited by 25
“A previous study using lipidomics on primary rat OPCs in culture found that OPCs differentiated into MOLs showed a distinct increase in saturated fatty acid levels, with a decrease in polyunsaturated fatty acid content relative to that in OPCs (44), suggestive of higher activation of Srebp-1 in MOLs than in OPCs.”
InfluentialTiane, A., Schepers, M., Reijnders, R. A., van Veggel, L., Chenine, S., Rombaut, B., Dempster, E. L., Verfaillie, C. M., Wasner, K., Grünewald, A., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02596-8 · Cited by 31
“Genes within these clusters ranged from important myelin genes (MBP, MAG) and genes that regulate myelin formation (CNTN2, LPAR1) or OPC differentiation (PARD3, BCAS1), to genes important for lipid metabolism (UGT8, ABCA2) (34–39).”
BackgroundLohrberg, M., Winkler, A., Franz, J., van der Meer, F., Ruhwedel, T., Sirmpilatze, N., Dadarwal, R., Löber-Handwerker, R., Esser, D. S., Wiegand, K., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01105-2 · Cited by 25
“Breast carcinomaamplified sequence 1 (BCAS1) has recently been characterized as a marker protein for a pre-myelinating and myelinating oligodendrocyte subpopulation derived from NG2-positive OPCs [26].”
BackgroundInfluentialSelf-citationCerebral Creatine Deficiency Affects the Timing of Oligodendrocyte Myelination
Rosko, L. M., Gentile, T., Smith, V. N., Manavi, Z., Melchor, G. S., Hu, J., Shults, N. V., Albanese, C., Lee, Y., Rodriguez, O. C., et al. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.2120-21.2022 · Cited by 23
“Moreover, TUNEL-positive cells did not colocalize with markers of OPCs or mature oligodendrocytes in the GamtGFP/GFP mice, but appeared colocalized with BCAS1, a marker of early myelinating oligodendrocytes (Fard et al., 2017) (Extended Data Fig.”
BackgroundNagai, L. A. E., Park, S., & Nakai, K. (2019) · BMC Medical Genomics · doi:10.1186/s12920-018-0437-8 · Cited by 22
“Bcas1 also shows evidence of coordination in early activation of restricted transcription in ES cells [30].”
BackgroundFerreira, S., Pitman, K. A., Summers, B. S., Wang, S., Young, K. M., & Cullen, C. L. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14726 · Cited by 22
“Scale bars represent 10 cm (e-f, i, k-l) and 25 cm (n-o) (a) (b) (c) (d) (e) (f) (g) (h) (i) (m) (n) (o) (p) (q) (r) (s) (t) (u) (j) (k) (l) oligodendrocytes (Fard et al., 2017).”
Bergner, C. G., Genc, N., Hametner, S., Franz, J., van der Meer, F., Mitkovski, M., Weber, M. S., Stoltenburg‐Didinger, G., Kühl, J., Köhler, W., et al. (2021) · Glia · doi:10.1002/glia.24042 · Cited by 23
Self-citationWiggermann, V., Endmayr, V., Hernández‐Torres, E., Höftberger, R., Kasprian, G. J., Hametner, S., & Rauscher, A. (2023) · Brain Pathology · doi:10.1111/bpa.13150 · Cited by 22
“In addition, immunohistochemical stainings for proteolipid protein (PLP), one of the major myelin proteins, CD68 for phagocytosing microglia/macrophages and BCAS1 staining for remyeli-nating oligodendrocytes were obtained [26].”
BackgroundKaji, S., Maki, T., Ueda, J., Ishimoto, T., Inoue, Y., Yasuda, K., Sawamura, M., Hikawa, R., Ayaki, T., Yamakado, H., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00997-4 · Cited by 22
Myelin is repaired by constitutive differentiation of oligodendrocyte progenitors
Mironova, Y. A., Dang, B., Heo, D., Xu, Y. K. T., Hsu, A. T.-W., von Bernhardi, J. E., Molina-Castro, G. C., Kim, A. A., LIN, J., Reich, D. S., et al. (2026) · Science · doi:10.1126/science.adu2896 · Cited by 28
Emerging small-molecule treatments for multiple sclerosis: focus on B cells
Gregson, A. M., Thompson, K. K., Tsirka, S. E., & Selwood, D. L. (2019) · F1000Research · doi:10.12688/f1000research.16495.1 · Cited by 20
Frazier, A. P., Mitchell, D. N., Given, K. S., Hunn, G., Burch, A. M., Childs, C. R., Moreno‐Garcia, M., Corigilano, M. R., Quillinan, N., Macklin, W. B., et al. (2023) · Glia · doi:10.1002/glia.24349 · Cited by 20
“Cells in clusters three and four had increased expression of Bcas1 and Tns3, genes upregulated in newly formed, pre-myelinating oligodendrocytes (supplemental figure 3D) [34, 35].”
BackgroundInfluentialDeng, X., Hu, Z., Zhou, S., Wu, Y., Fu, M., Zhou, C., Sun, J., Gao, X., & Huang, Y. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14510 · Cited by 19
“88 All these indications suggest that cell clusters 6 and 7 may be more inclined to form mature oligodendrocytes.”
BackgroundAchiro, J. M., Tao, Y., Gao, F., Lin, C.-H., Watanabe, M., Neumann, S., Coppola, G., Black, D. L., & Martin, K. C. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1334862 · Cited by 21
Microglia regulate cortical remyelination via TNFR1-dependent phenotypic polarization
Boutou, A., Roufagalas, I., Politopoulou, K., Tastsoglou, S., Abouzeid, M., Skoufos, G., de Juan, L. V., Ko, J. H., Kyrargyri, V., Hatzigeorgiou, A. G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114894 · Cited by 22
Huitema, M. J. D., Strijbis, E. M. M., Luchicchi, A., Bol, J. G. J. M., Plemel, J. R., Geurts, J. J. G., & Schenk, G. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312634 · Cited by 16
“, report on BCAS1 as a marker for early myelinating oligodendrocytes that are found in a proportion of chronic white matter lesions of patients with MS [36].”
BackgroundMayerl, S. E., & Heuer, H. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106195 · Cited by 15
“Of note, putative alterations in the proportion of pre-myelinating oligodendrocytes remain elusive and should further be assessed using antibodies against stage-specific marker proteins such as Bcas1 (breast carcinoma amplified sequence 1) (Fard et al., 2017).”
Distinct transcriptional changes distinguish efficient and poor remyelination in multiple sclerosis
Chen, J. Q. A., McNamara, N. B., Engelenburg, H. J., Jongejan, A., Wever, D. D., Hopman, K., van Rixel, E., Nijhuis, P. J. H., de Winter, F., Moerland, P. D., et al. (2025) · Brain · doi:10.1093/brain/awae414 · Cited by 17
“However, quantification of the active remyelination marker BCAS1 47 did not show differences be-tween RLs, ALs non-foamy, ALs foamy and NAWM.”
InfluentialLuchicchi, A., González, G. M., Halperin, S. T., Strijbis, E. M. M., van Dijk, L. H. M., Foutiadou, C., Uriac, F., Bouman, P. M., Schouten, M. A. N., Plemel, J. R., et al. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52015 · Cited by 16
Microglia contributes to remyelination in cerebral but not spinal cord ischemia
Pavic, G., Petzsch, P., Jansen, R., Raba, K., Rychlik, N., Simiantonakis, I., Küry, P., Göttle, P., Köhrer, K., Hartung, H., et al. (2021) · Glia · doi:10.1002/glia.24068 · Cited by 17
“Furthermore, microglia depletion led to a reduction of Bcas1/Sox10 (Fard et al., 2017) double positive cells, affirming a role for microglia in remyelination after ischemia.”
BackgroundHassel, L. A., Fröb, F., Küspert, M., Hillgärtner, S., Arnold, P., Huang, W., Kirchhoff, F., & Wegner, M. (2023) · Glia · doi:10.1002/glia.24373 · Cited by 15
“The beginning differentiation was also evident from Bcas1 expression as a marker that is turned on early during the differentiation process in pre-myelinating oligodendrocytes (Figure 3a,b) (Fard et al., 2017).”
BackgroundShorrock, H. K., Lennon, C. D., Aliyeva, A., Davey, E. E., DeMeo, C. C., Pritchard, C. E., Planco, L., Vélez, J. M., Mascorro-Huamancaja, A., Shin, D. S.-H., et al. (2023) · Brain · doi:10.1093/brain/awad329 · Cited by 17
“67,68 70-74 These data indicate that, at the level of pathways and individual genes, dysregulation of alternative splicing could contribute to disruption of cellular processes known to be implicated in pathogenesis of ataxia.”
Background
Metadata
- Authors
- Fard, M. K., van der Meer, F., Sánchez, P., Cantuti-Castelvetri, L., Mandad, S., Jäkel, S., Fornasiero, E. F., Schmitt, S., Ehrlich, M., Starost, L., Kuhlmann, T., Sergiou, C., Schultz, V., Wrzos, C., Brück, W., Urlaub, H., Dimou, L., Stadelmann, C., & Simons, M.
- Affiliations
- Max Planck Institute of Experimental Medicine (DE)
- Universitätsmedizin Göttingen (DE)
- Max Planck Institute for Experimental Medicine, 37075 Göttingen, Germany.
- Ludwig-Maximilians-Universität München (DE)
- University Hospital Münster (DE)
- Max Planck Institute for Molecular Biomedicine (DE)
- Universität Ulm (DE)
- German Center for Neurodegenerative Diseases (DE)
- Corresponding author
- Fard, Maryam K.
- van der Meer, Franziska
- Stadelmann, Christine
- Simons, Mikael
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-12-06
- Volume
- 9
- Issue
- 419
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC7116798
- OpenAlex
- W2771504695
- Cited by
- 249
- References
- 49
- Citations by year
- 2026: 35 · 2025: 37 · 2024: 44 · 2023: 36 · 2022: 31 · 2021: 23 · 2020: 24 · 2019: 14 · 2018: 5
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Max Planck Digital Library (submittedVersion, other-oa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- DZNE Pub (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- ERC CoG (award297874, 647168)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- BCAS1, oligodendrocytes, myelination, remyelination, multiple sclerosis, demyelination, white matter lesions, remyelination therapy
- MeSH terms
- Animals, Demyelinating Diseases, Humans, Multiple Sclerosis, Myelin Sheath, Neoplasm Proteins, Oligodendroglia, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
